Price
$1.19
Increased by 0.00%
Dollar Volume (20D)
506.31 K
ADR%
9
Earnings Report Date (estimate)
Aug 2, 23 (-0.49)
Market Cap.
51.10 M
Shares Float
17.64 M
Shares Outstanding
42.94 M
Beta
2.38
Price / Earnings
-0.59
BPR
118.14
20D Range
1.02 1.34
50D Range
0.86 1.38
200D Range
0.84 2.41
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 4, 23 -0.53
Increased by +36.90%
-0.48
Decreased by -21.70%
Mar 9, 23 -0.51
Increased by +42.70%
-0.47
Decreased by -18.11%
Nov 2, 22 -0.44
Increased by +43.59%
-0.58
Increased by +41.62%
Aug 4, 22 -0.47
Increased by +40.51%
-0.67
Increased by +44.55%
May 4, 22 -0.84
Decreased by -13.51%
-0.73
Decreased by -20.64%
Mar 10, 22 -0.89
Increased by +18.35%
-0.83
Decreased by -8.71%
Nov 4, 21 -0.78
Increased by +92.91%
-0.81
Increased by +4.57%
Aug 5, 21 -0.79 -0.81
Increased by +3.05%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 2.72 M
Increased by +5.91%
-22.95 M
Increased by +35.55%
Decreased by -843.00%
Increased by +39.14%
Dec 31, 22 3.54 M
Increased by +863.76%
-21.89 M
Increased by +41.97%
Decreased by -618.77%
Increased by +93.98%
Sep 30, 22 4.11 M
Increased by +167.14%
-18.62 M
Increased by +43.78%
Decreased by -453.51%
Increased by +78.96%
Jun 30, 22 3.69 M
Increased by +139.03%
-19.92 M
Increased by +33.18%
Decreased by -539.51%
Increased by +72.05%
Mar 31, 22 2.57 M
Increased by +182.53%
-35.62 M
Decreased by -28.69%
Decreased by -1.39 K%
Increased by +54.45%
Dec 31, 21 367.00 K
Increased by +N/A%
-37.71 M
Decreased by -9.57%
Decreased by -10.28 K%
Decreased by N/A%
Sep 30, 21 1.54 M
Increased by +N/A%
-33.12 M
Increased by +0.52%
Decreased by -2.16 K%
Decreased by N/A%
Jun 30, 21 1.54 M
Increased by +N/A%
-29.82 M
Decreased by -43.38%
Decreased by -1.93 K%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.